NEW POTENTIALS FOR THE OPTIMIZATION OF THERAPY OF DEPRESSION IN GERONTOPSYCHIATRIC PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the comparative evaluation of the efficacy and safety of monotherapy with one of the new generation antidepressants and combined therapy with the use of similar antidepressants and citicoline for the treatment of depression in elderly patients. The study included patients of gerontopsychiatric hospital aged 60 to 79 years with mild to moderate depression. Citicoline was administered intravenously using courses of intravenous infusions, after that the drug was administered per os in the form of a solution. For the evaluation of the therapeutic efficacy (in accordance with a specially designed protocol), standardized rating scales were used. The results led to the following conclusion: the use of combination therapy allows to achieve more rapid development of therapeutic response and a more pronounced effect than monotherapy with antidepressant.

Full Text

Restricted Access

About the authors

Ya. B Kalyn

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

S. I Gavrilova

FSBIS “Scientific Center of Mental Health"

Email: sigavrilova@yandex.ru
MD, Prof., Head of the Division of Geriatric Psychiatry Moscow

T. P Safarova

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

O. B Yakovleva

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

V. S Sheshenin

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

V. V Kornilov

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

E. S Shipilova

FSBIS “Scientific Center of Mental Health"

Division of Geriatric Psychiatry Moscow

References

  1. Гаврилова С.И., Калын Я.Б. Социально-средовые факторы и состояние психического здоровья пожилого населения (клиникоэпидемиологическое исследование). Вестник РАМН. 2002;9:15-20.
  2. Sheehan B., Karim S., Burns A. Mood disorders. In: Old age psychiatry. Oxford University Press, 2009. P. 95-124.
  3. Blazer D.G. Depression in late life: review and commentary. J. Gerontol. Biol. Med. Sci. 2003;58:249-265.
  4. Ватолина М.А., Самородская И.В., Бойцов С.А. Потерянные годы жизни и смертность в результате болезни Альцгеймера в России. Психиатрия. 2014;1:49-53.
  5. Baldwin R., Wild R. Management of depression in later life. Advances in Psychiatric Treatment. 2004;10:131-39.
  6. Katona C., Livingston G. How well do antidepressants work in older people? A systematic review of Number Needed to Treat. J. Affective Disorders. 2002;69:47-52.
  7. Bondy B. Dialogys in clinical neuroscience. 2002;4:7-20.
  8. Alexopoulos G.S. Frontostriatal and limbic dysfunction in late-life depression. Am. J. Geriatr Psychiatry. 2002;10:687-95.
  9. Sexton C.E., Le Masurier M., Allan C.L., et all. Magnetic resonance imaging in late-life depression: vascular and glucocorticoid cascade hypotheses. Br. J. Psychiatry. 2012; 201(1):46-51.
  10. Papakostas G.I., Culpepper L. Understanding and managing cognition in the depressed patient. J. Clin. Psychiatry. 2015;76(4):418-25.
  11. Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014;28(3):185-93.
  12. Secades J.J. CDP-choline and clinical review, 2010 update. Rev Neurol. 2011;52(Suppl. 2):S1-S62.
  13. Gareri P., Castagna A., Cotroneo A.M., Putignano S., De Sarro G., Bruni A.C. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin. Interv. Aging. 2015 Sep 3;10:1421-29.
  14. Wignall N.D., Brown E.S. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014 Jul;40(4):262-68.
  15. José Álvarez-Sabín, Gustavo C. Román. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. BrainSci. 2013 Sep; 3(3): 1395-1414.
  16. Гаврилова С.И. Возможности применения цитиколина в гериатрической психиатрии и неврологии в рамках мультимодальной терапии нейродегенеративных и церебрально-сосудистых заболеваний. Журнал Современная терапияв психиатрии и неврологии, 2014. № 3. С. 24-30.
  17. Secades J.J. Probable role of citicoline in stroke rehabilitation: review of the literature. Rev Neurol. 2012;54:173-79.
  18. Parnetti L., Mignini F., Tomassoni D., Traini E., Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J. Neurol. Sci. 2007;257:264-69.
  19. Adibhatla R.M., Hatcher J.F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J. Neurosci. Res. 2002;70:133-139.
  20. Lee H.J., Kang J.S., Kim Y.l. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J. Clin. Neurol. 2009;5:33-8.
  21. Teather L.A., Wurtman R.J. Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory deficits in aging rats. ProgNeuropsychopharmacolBiolPsychiatry 2003;27:711-71.
  22. Lozano F.R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung. 1983;33: 1073-80.
  23. Roberti G., Tanga L., Michelessi M., Quaranta L., Parisi V., Manni G., Oddone F. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. lnt. J. Mol. Sci. 2015;16(12):28401-17.
  24. Roberti G., Tanga L., Parisi V., Sampalmieri M., Centofanti M., Manni G. A preliminary study of the neuroprotective role of Citicoline eye drops in glaucomatous optic neuropathy. Indian. J. Ophthalmol. 2014;62:549-53.
  25. Гаврилова С.И., Калын Я.Б., Сафарова Т.П., Яковлева О.Б., Шешенин В.С., Корнилов В.В., Шипилова Е.С. Оптимизация антидепрессивной терапии в условиях геронтопсихиатрического стационара. Журн. неврол. и псих. им. С.С. Корсакова. 2015;2(6):46-54.
  26. Калын Я.Б., Сафарова Т.П., Шешенин В.С., Гаврилова С.И. Сравнительная эффективность и безопасность антидепрессивной моно- и мультимодальной терапии у пожилых больных депрессией (опыт клинического применения в геронтопсихиатрическом стационаре). Журн. неврол. и псих. им. С.С. Корсакова. 2014;2(6):20-9.
  27. Гаврилова С.И., Федорова Я.Б., Гантман М.В., Калын Я.Б., Колыхалов И.В. Цераксон (цити колин) в лечении синдрома мягкого когнитивного снижения. Журн. неврол. и псих. им. С.С. Корсакова. 2011;12:16-20.
  28. Putignano S., Gareri P., Castagna A., Grella R., Lacava R., Maddonni A., Marino S., Pluderi A., Putignano D., Rocca F. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin. Int. Aging. 2012;7:113-18.
  29. Garcia-Cobos R., Frank-Garcia A., Gutierrez-Fernandes M., Diez-Tejedor E. Citicoline, use in cognitive decline vascular and degenerative. J. Neurol. Sci. 2010;299(1-2): 188-92.
  30. Agnoli A. Bruno G., Fioravanti M. Therapeutic approach to senile memory impairment: a doubleblind clinical trial with CDP-choline. In: Wurtman R.J.,Corkin S., Grouden J.S., eds. Alzheimer's disease: Proceedings of the Fifth Meeting of the International Study Group on the pharmacology of Memory Disorders Associated with Aging. Boston, MABirkhauser, 1989. P. 649-54.
  31. Secades J.J., Alvarez-Sabin J., Rubio F., Lozano R., Davalos A., Castillo J. Trial Investigators. Citicoline in intracerebral haemorrhage: a doubleblind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc. Dis. 2006;21(5-6):380-85.
  32. Spiers P.A., Myers D., Mochanadel G.S., Lieberman H.R., Wurman R.J. Citicoline improves verbal memory in aging. Arch. Neurol. 1996;53:441-48.
  33. Milani M. Citicoline as coadiuvant treatment of cognitive impairment in chronic degenerative Central Nervous System diseases and in ischemic stroke: A review of available data. Online J. Med. Medical Sci. Res. 2003;2(2):13-18.
  34. Skripuletz T., Manzel A., Gropengießer K., Schäfer N., Gudi V., Singh V., Salinas Tejedor L., Jörg S.,Hammer A., Voss E., Vulinovic F., Degen D., Wolf R., Lee D.H., Pul R., Moharregh-Khiabani D., Baumgärtner W., Gold R., Linker R.A., Stangel M. Pivotal role of choline metabolites in remyelination. Brain. 2015;138(Pt 2): 398-413.
  35. Ishizaki J., Yamamoto H., Takahashi T., Takeda M., Yano M., Mimura M. Changes in regional cerebral blood flow following antidepressant treatment in late-life depression. Int J Geriatr Psychiatry 2008;23:805-11.
  36. Colloby S.J., Firbank M.J., He J., Thomas A.J., Vasudev A., Parry S.W., O'Brien J.T. Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study. Br. J. Psychiatry. 2012;200(2):150-55.
  37. Alvarez-Sabín J., Ortega G., Jacas C., Santamarina E., Maisterra O., Ribo M., Molina C., Quintana M., Román G.C. Long-Term Treatment with Citicoline May Improve Poststroke Vascular Cognitive Impairment. Cerebrovasc. Dis. 2013; 35:146-54.
  38. Gruber S.A., Sagar K.A., Dahlgren M.K., Gonenç A., Conn N.A., Winer J.P., Penetar D., Lukas S.E. Citicoline Treatment Improves Measures of Impulsivity and Task Performance in Chronic Marijuana Smokers: A Pilot BOLD fMRI Study. Int. J. Neurol. Neurother. 2015;2(3):1-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies